ERBB2 and neoplasm: Taken together, these results suggest that trastuzumab is an effective reagent for the treatment of HER2-positive GC, and the plasma HER2 ratio determined by ddPCR may serve as a biomarker for tumor progression in GC patients who received treatment with trastuzumab.